GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Fairfax - Cheap Portfolio Insurance

March 14, 2012 | About:
The Science of Hitting

The Science of Hitting

228 followers
In September of last year, GuruFocus interviewed Prem Watsa (link here), chairman and chief executive of Fairfax Financial Holdings (FRFHF); here are some of the interesting things Mr. Watsa had to say about Fairfax and its valuation (bold added for emphasis):

Watsa: So we have a 15% compounded growth rate, and we think that growth rate continues to be achievable for us. Our capital base is about $8 billion, our investment portfolio is at $24 billion, business premiums are written at about $5 billion, we have international businesses, if you take our equity holdings in companies like ICICI Lombard and the Chinese company, Alltrust, and the others we list in our annual report, at about another $1.5 billion, so we have about $6.5 billion in aggregate premium. So it’s significantly larger than where we began 25 years ago, but in terms of the world markets, we think that there's a lot of opportunity to grow over time and make a 15% real return, which is making an underwriting profit plus interest and dividend income plus capital gains all after-tax. So you put all of that together, we figure mark-to-market book value, including the dividends that we pay out, will over time compound book value at 15% a year. But you know we're not quarterly focused, we've never issued guidance, we've never given any quarterly numbers, so we're focused on performing over a long period of time.

GuruFocus: So you feel comfortable over the long term, 15% is still achievable.

Watsa:Yes, that rate of return continues to be our goal.

In regards to Fairfax’s intrinsic value, Prem had this to say:

Watsa: Our book value at the end of June of this year was approximately $360 per share, as reported in our quarterly statement. But about intrinsic value, if you look at the fact that our rate of return has been very significant over 5 years, 10 years, 15 years, 25 years, then the intrinsic values of our companies are significantly higher than our book value. Change in book value is not a bad way of looking at change in intrinsic value, but if you think we can make 15% a year as our target, we've achieved better than that in the past, nothing to say we'll achieve that in the next five years, but if we do, then of course the intrinsic value of our company is significantly higher than our book value.

GuruFocus: But you cannot put a number on it?

Watsa: No, that's what I leave for you and all the analysts and everyone who follows us.

While Prem still hasn’t put a number on it, his wording on page 10 of his 2011 letter to shareholders (which came out last Friday) suggests that the shares are increasingly attractive (from his perspective):

“Our stock price is currently reflecting the short term volatility of earnings rather than the buildup of long term intrinsic value. We think you will see the long term intrinsic value being reflected in time (we hope!!).”

At roughly $400 per share, Fairfax trades around 1.1x book (as reported at the end of FY2011); not only that, but the company has two other components (besides the valuation and a strong track record) that might peak equity investor’s interests:

1. CPI Linked Derivative Contracts – these contracts are marked to market, and have been written down to $208 million as of the end of the year – essentially, if they expire worthless, the impact is relatively small; on the other hand of the spectrum, these positions are worth billions in the case of deflation through 2020, and would lead to huge gains.

2. Hedged Equity Portfolio – At the end of the year, the portfolio was 104.6% hedged; the company’s long term equity holdings are in three names – Wells Fargo (WFC), Johnson & Johnson (JNJ), and US Bancorp (USB).

From my perspective, this is the definition of insurance: limited downside, but an attractive way to hedge against equity declines or long term deflation. For investors considering buying treasuries or TIPS, it may be worth their time to take a second look at Fairfax Financial.

About the author:

The Science of Hitting
I'm a value investor, with a focus on patience; I look to buy great companies that are suffering from short term issues, and hope to load up when these opportunities present themselves. As this would suggest, I run a fairly concentrated portfolio by most standards, usually with 8-10 names; from the perspective of a businessman rather than a market participant / stock trader, I believe this is more than sufficient diversification.

I hope to own a collection of great businesses; to ever sell one, I would demand a substantial premium to the average market valuation due to what I believe are the understated benefits to the long term investor of superior fundamentals and time on intrinsic value. I don't have a target when I purchase a stock; my goal is to replicate the underlying returns of the business in question - which if I've done my job properly, should be very attractive over many years.

Rating: 4.3/5 (17 votes)

Comments

ramands123
Ramands123 - 2 years ago


does anyone know how can one buy these CPI's deivatives? or is it just for institunal investors
The Science of Hitting
The Science of Hitting premium member - 2 years ago
I don't think you can, but not positive....
ryan_sequeira
Ryan_sequeira - 2 years ago


I'm also looking to buy these CPI-linked derivatives, so if anyone knows, please help out! Thanks

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide